Capricor Therapeutics (NASDAQ:CAPR) Lowered to “Neutral” Rating by Cantor Fitzgerald
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) was downgraded by investment analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research note issued on Thursday. They currently have a $3.50 target price on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential downside of 47.53% from the […]
30 Jul 13:06 · The Markets Daily